| David Ramm, | |
|
2613 E Union St, #2, Seattle, WA 98122-3161 | |
| (206) 419-8734 | |
| Not Available |
| Full Name | David Ramm |
|---|---|
| Gender | Male |
| Speciality | Speech-language Pathologist |
| Location | 2613 E Union St, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346612611 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL 60594312 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Ramm, 2613 E Union St, #2, Seattle, WA 98122-3161 Ph: (206) 419-8734 | David Ramm, 2613 E Union St, #2, Seattle, WA 98122-3161 Ph: (206) 419-8734 |
News Archive
Research from King's College in London, UK, and Lund University in Sweden could explain why diabetes drugs which have worked in animal experiments are not equally successful in humans.
AssistMed, Inc. today announced the release of a data transformation platform, Duet™, that enables healthcare professionals to dictate or handwrite medical information and receive it back securely as digital input for their healthcare information systems.
Recalling painful memories while under the influence of the drug metyrapone reduces the brain's ability to re-record the negative emotions associated with them, according to University of Montreal researchers at the Centre for Studies on Human Stress of Louis-H. Lafontaine Hospital.
The Alberta Diabetes Surveillance System was created in 2006 in partnership between Alberta Health and Wellness and the Institute of Health Economics. Led by Jeff Johnson in the University of Alberta's School of Public Health, the group has been identifying trends in diabetes, its associated health conditions and monitoring trends in accessing health-care services and has published a comprehensive report called a Diabetes Atlas every two years.
Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.
› Verified 2 days ago
Amy L Donaldson, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Autism Ctr, Box 357920, Seattle, WA 98195 Phone: 206-897-1801 | |
Ms. Carol L Ray, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4507 Sunnyside Ave N, Unit D, Seattle, WA 98103 Phone: 206-849-3937 | |
Ms. Linda E Eblen, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4800 Sand Point Way Ne, Mail Stop W-6839, Seattle, WA 98105 Phone: 206-987-6164 | |
Mrs. Genevieve Houdet-cote, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Ms:h4-pmr, Seattle, WA 98101 Phone: 206-341-0461 | |
Daelene King, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9100 5th Ave Ne, Seattle, WA 98115 Phone: 206-526-2662 | |
Molly Beier, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-744-3000 | |
Vassalo Speech And Language Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2300 W Bertona St, Seattle, WA 98199 Phone: 978-444-0321 |